Time Course of Changes in μ-Opioid Receptor mRNA Levels in the Periaqueductal Gray of Rat Brain by a Single or Repeated Injections of Antisense Oligodeoxynucleotides

• Published in: Japanese journal of pharmacology 1999, Vol.81(2), pp.209-215
• Main Authors: Yoshikawa, Masanobu, Yokogami, Kouichi, Kitamura, Ken, Kobayashi, Tomomi, Kanai, Masayuki, Taniguchi, Takao, Akahori, Kazuhito, Nakabayashi, Masaru, Iwao, Kayoko, Hyodo, Masao, Oka, Tetsuo
• Format: Article
• Language: English
• Subjects: Animals; Antisense oligodeoxynucleotide; Indicators and Reagents; Male; mRNA level; Oligonucleotides, Antisense - administration & dosage; Oligonucleotides, Antisense - pharmacology; Periaqueductal Gray - physiology; Rats; Rats, Wistar; Receptors, Opioid, mu - biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - analysis; RNA, Messenger - biosynthesis; RNA, Messenger - isolation & purification; RT-PCR (reverse transcription-polymerase chain reaction); μ-Opioid receptor
• ISSN: 0021-5198; 1347-3506
• DOI: 10.1254/jjp.81.209

The effect of phosphorothioated antisense oligodeoxynucleotide (AS ODN) against the μ-opioid receptor (MOR) on MOR mRNA level in the periaqueductal gray (PAG) of rat brain was investigated. The MOR mRNA levels at 3, 6, 12, 24, 48 and 72 h after MOR AS ODN microinjection into the PAG were determined by reverse transcriptase-polymerase chain reaction. The MOR mRNA level was significantly decreased only at 12 h after the injection of 10 μg MOR AS ODN. When 10 μg MOR AS ODN was given three times at the interval of 48 h, MOR mRNA levels were significantly decreased at 6, 12 and 24 h after the last injection of the AS ODN. However, MOR mRNA levels were not significantly changed by three injections at 48-h interval of MOR sense ODN or AS ODNs against δ- and κ-opioid receptors, although the two latter AS ODNs significantly reduced the respective targeted mRNA levels. In conclusion, the present results show that the selective decrease in MOR mRNA is at least one reason why the reported diminished effects of MOR agonists are produced in animals pretreated with MOR AS ODN, although they could be produced through several mechanisms in which MOR mRNA level does not change.